2026 Keyword Index

A

  • advanced spinal ankylosis, 195
  • Adverse effects, 122
  • adverse events, 108
  • age at symptom onset, 286
  • age group, 37
  • albumin, 98
  • anakinra, 309
  • ANCA-associated vasculitis, 173
  • ankle rash, 24
  • Ankylosing spondylitis, 37, 195, 302, 313
  • anti-TNF, 140, 253
  • antirheumatic agents, 56
  • Antirheumatic treatments, 150
  • anxiety, 302
  • APS, 98
  • aterosclerosis, 43
  • autoimmune hemolytic anemia, 244
  • autoinflammatory disease, 309
  • awareness, 50
  • axial pain, 313
  • axial spondyloarthritis, 195

B

  • B-cell therapy, 235
  • balance, 37
  • bamboo spine, 195
  • baricitinib, 108
  • BASMI, 89
  • bDMARD, 140, 253
  • bDMARDs, 195
  • Behçet’s disease, 302
  • Behçet’s syndrome, 295
  • biologic DMARDs, 65
  • biologic therapy, 140, 253

C

  • C-reactive protein, 98
  • capillaroscopy, 295
  • Cardiac amyloidosis, 82
  • cardiac magnetic resonance, 82
  • carotis intima media, 43
  • characteristics of patients lost to follow-up, 31
  • Childhood, 75
  • clinical phenotypes, 235
  • clinical sub-phenotypes, 286
  • consensus report, 262
  • COVID-19, 119
  • cross-cultural adaptation, 167
  • cyclophosphamide, 10
  • cytokines, 43

D

  • Delphi consensus, 140, 253
  • depression, 302
  • diagnostic delay, 286
  • diagnostic yield, 204
  • Diastolic dysfunction, 280
  • diet, 215
  • differential diagnosis, 82
  • diffuse alveolar hemorrhage, 227
  • disease severity, 75
  • DMARDs resistance, 122
  • drug retention, 173

E

  • echocardiography, 280
  • eosinophilic granulomatosis with polyangiitis (EGPA), 10
  • erysipelas-like erythema, 24
  • extra-musculoskeletal manifestations, 286

F

G

  • gender, 37
  • glucocorticoids, 10
  • gout, 1, 119
  • granulomatosis with polyangiitis (GPA), 10

H

  • hemophagocytic syndrome, 244
  • Hepatitis B, 262
  • hepatitis C, 262
  • hepatitis D, 262
  • histopathology, 204
  • hyperuricemia, 1, 119

I

  • IgG4-related disease, 235
  • IgM monoclonal gammopathy, 309
  • IGRA, 140, 253
  • IL-17 inhibitors, 65
  • immunization, 150
  • immunological endotypes, 235
  • immunophenotype, 204
  • immunosuppressive therapy, 10, 262
  • inebilizumab, 235
  • infections, 10
  • Inflammatory arthritis, 204
  • inflammatory cardiomyopathy, 82
  • interleukin-1 blockade, 309
  • interstitial lung disease, 181, 227

J

  • JAK1 inhibitor, 122
  • Juvenile idiopathic arthritis, 215

L

  • late gadolinium enhancement, 82
  • Latent tuberculosis, 140, 253
  • leucopenia, 244
  • lupus erythematosus, 75
  • lymphopenia, 244

M

  • major adverse cardiovascular events, 108
  • MEFV mutation, 24
  • microcirculation, 295
  • microscopic polyangiitis (MPA), 10
  • mortality, 98
  • mSASSS, 89

N

  • nephritis, 98
  • neutropenia, 244
  • nutritional status, 215
  • nutritional supplements, 215

O

  • ochronotic spondylopathy, 313
  • organ involvement, 75

P

  • P4, 167
  • pain, 167
  • parotid gland, 181
  • personality traits, 188
  • physician-patient relations, 188
  • plasma exchange, 10
  • pleural involvement, 227
  • Polimyalgia romatica, 43
  • professional burnout, 188
  • Psoriasis, 1
  • psoriatic arthritis, 1
  • psout, 1
  • pulmonary involvement, 227

R

  • Radiographic axial spondyloarthritis, 89
  • real life, 108
  • real-world data, 173
  • reasons for patients lost to follow-up, 31
  • rehabilitation, 50
  • reliability, 167
  • renal involvement, 173
  • reproductive counseling, 302
  • retention rate, 195
  • rheumatic diseases, 140, 150, 253, 262, 295
  • rheumatoid arthritis, 108, 280
  • Rheumatology, 50
  • risk factors, 98
  • rituximab, 10, 173

S

  • sacroiliac joint ankylosis, 89
  • Schnitzler syndrome, 309
  • serum amyloid A, 273
  • sex differences, 56
  • shrinking lung syndrome, 227
  • Sjögren’s disease, 181
  • spinal mobility, 37, 89
  • Spondyloarthritis, 65, 286
  • structural damage, 89
  • surveys and questionnaires, 188
  • survival analysis, 98
  • synovial tissue, 204
  • Systematic literature review, 130
  • systemic immune-inflammation index, 273
  • Systemic lupus erythematosus, 98, 227, 244

T

  • Takayasu arteritis, 56
  • therapeutic stratification, 235
  • thrombocytopenia, 244
  • thrombotic microangiopathy, 130, 244
  • TNF inhibitors, 65
  • treatment resistance, 65
  • treatment response, 195
  • tsDMARD, 140, 253
  • tuberculin skin test, 140, 253

U

  • ultrasonography, 181
  • ultrasound-guided synovial biopsy, 204

V